Home / Business and Economy / Novo Nordisk and Eli Lilly Deny Telehealth Partnership Claims
Novo Nordisk and Eli Lilly Deny Telehealth Partnership Claims
14 Nov
Summary
- Novo Nordisk and Eli Lilly reject partnership claims by Mangoceuticals
- Spokespeople for both companies confirm no special arrangements with Mangoceuticals
- Mangoceuticals did not respond to requests for comment
On November 13th, 2025, telehealth company Mangoceuticals Inc. issued a press release claiming to have weight-loss drug partnerships with leading pharmaceutical firms Novo Nordisk and Eli Lilly. However, as of November 14th, 2025, spokespeople for both Novo Nordisk and Eli Lilly have firmly denied these allegations.
In emails to Reuters, representatives for the two drug makers stated they have no special arrangements with Mangoceuticals. The companies have rejected the partnership claims made by Mangoceuticals in its recent press release.
Attempts by Reuters to reach Mangoceuticals for comment on the matter have so far been unsuccessful, as the company has not responded to requests. The conflicting statements have cast doubt on the validity of Mangoceuticals' earlier announcement regarding its purported partnerships with the pharmaceutical giants.
